Regulation & governance

From Patients to Customers: GLP-1 Marketing Is Rewriting Obesity Care

Retatrutide Isn’t Approved. Online, ‘Reta’ Is Already a Weight-Loss Brand

Pembrolizumab Just Lost a Head-to-Head Survival Fight

SMA Treatment Finally Reaches the Muscle

HER2-Mutant Lung Cancer Just Moved Into First Line

One Psychedelic Dose Is Now a Phase III Argument

Can Belgium Turn Routine GP Data Into Cardiovascular Prevention?

MOGAD Is Close to Its First Real Treatment

Breast Cancer Just Proved Why Biomarker Selection Matters
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
